



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes**  
**August 21, 2024**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the “Oversight Committee Board Packet” section for the corresponding meeting date.

**Call to Order – Agenda Item 1**

Presiding Officer Dr. David Cummings announced a quorum present and called the meeting to order at 8:30 a.m.

**Roll Call/Excused Absences – Agenda Item 2**

Committee Members Present

David Cummings, M.D.  
Ambrosio Hernandez, M.D.  
Donald (Dee) Margo  
Will Montgomery (via video)  
Mahendra Patel, M.D., P.A.  
Cindy Barberio Payne  
Bill Rice, M.D.  
Craig Rosenfeld, M.D.  
Thomas (Tommy) Taylor

Committee Members Absent

None

**Oath of Office – Agenda Item 3**

Presiding Officer Dr. Cummings welcomed the Oversight Committee’s newest member, Thomas A. Taylor, appointed in June by Lieutenant Governor Dan Patrick. Presiding Officer Dr. Cummings administered the Oath of Office to Mr. Taylor.

**Adoption of Minutes from the May 15, 2024, Meetings – Agenda Item 4, Tab 1**

**MOTION:**

On a motion by Dr. Rice and seconded by Dr. Hernandez, the Oversight Committee voted unanimously to approve the minutes of the May 15 Oversight Committee meeting as presented.

**Public Comment – Agenda Item 5**

Presiding Officer Dr. Cummings noted for the record that no member of the public asked to provide comments.

**Chief Executive Officer Report – Agenda Item 6, Tab 2**

Presiding Officer Dr. Cummings recognized Chief Executive Officer Kristen Doyle to present her report.

**Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 7, Tab 3**

Presiding Officer Dr. Cummings recognized Chief Compliance Officer Vince Burgess and Compliance Program Manager Stephen Nance to present the compliance report. Mr. Nance presented the compliance report for the past quarter’s activities.

There were no questions for Mr. Nance following his presentation.

Mr. Burgess presented the Compliance Certification for the proposed academic research grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

**Chief Scientific Officer Report – Agenda Item 8, Tab 4**

Presiding Officer Dr. Cummings recognized Chief Scientific Officer Dr. Michelle Le Beau to provide the Academic Research Program update and introduce the Program Integration Committee’s Grant Award recommendations.

As part of her program update, Dr. Le Beau presented the six FY 2024 Cycle 2 requests for applications (RFAs) for the committee’s consideration: Core Facility Support Awards, High-Impact/High-Risk Research Awards, Early Clinical Investigator Awards, TREC: Core Facility Support Awards, TREC: Advancing Innovative Individual Research Awards at TREC-Eligible Institutions, and TREC: Pilot Study Award.

Following her program update, Dr. Le Beau presented the Scientific Review Council and Program Integration Committee (PIC) award recommendations for the FY2024 Cycle 2 and Recruitment Cycle 24.12. The five award slates include 36 recommended grants totaling \$60.6 million.

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Budget
1	RP240545	CFSA	1.0	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000
2	RR240070	RFTTFM	1.0	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Budget
3	RR240076	RFTTFM	1.0	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
4	RR240082	RFTTFM	1.2	Identification of Neural Mechanisms Contributing to Chemotherapy- Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000
5	RP240610	CFSA	1.4	UTHealth Cancer Genomics Core (UTHealth CGC)	Zhao, Zhongming	The University of Texas Health Science Center at Houston	\$2,000,000
6	RP240478	CIA	1.4	Advancing immunotherapy for high-risk cancers in children and adolescents	Hegde, Meenakshi	Baylor College of Medicine	\$1,030,892
7	RP240473	CIA	1.6	Signal-Augmented Cancer Cell Therapies: Integrating Advanced Correlatory Studies and Mentorship	Omer, Bilal	Baylor College of Medicine	\$1,046,414
8	RP240494	CFSA	1.7	Children's Research Institute Metabolomics Core: Advanced Methodologies in Cancer Metabolism	DeBerardinis, Ralph	The University of Texas Southwestern Medical Center	\$2,601,616
9	RP240497	CFSA	1.7	Advanced Spatial Genomics Core Facility	Navin, Nicholas	The University of Texas M. D. Anderson Cancer Center	\$2,999,993
10	RR240079	RFTTFM	1.7	Immune surveillance and elimination of aneuploid cells in vivo	Trakala, Marianna	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
11	RP240432	CFSA	1.8	Advanced Multiparameter Cytometry and Cell Sorting Core	Beeton, Christine	Baylor College of Medicine	\$1,999,882
12	RP240440	MIRA2	1.8	Novel Therapies for Osteosarcoma	Gorlick, Richard	The University of Texas M. D. Anderson Cancer Center	\$4,498,684
13	RP240557	CIA	1.8	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727
14	RP240430	CFSA	1.9	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000
15	RP240590	HIHRA	2.0	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Budget
16	RP240539	HIHRRA	2.0	Spectroscopy for quantitative real-time imaging of radical formation in ultra-high dose rate radiation therapy	Gustavsson, Anna- Karin	Rice University	\$250,000
17	RP240508	CFSA	2.1	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778
18	RP240446	HIHRRA	2.1	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561
19	RP240442	CIA	2.1	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682
20	RP240559	CFSA	2.1	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763
21	RP240441	CIA	2.2	Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,098,945
22	RP240438	MIRA2	2.2	Overcoming major barriers to the delivery of successful T-cell immunotherapies	Rooney, Cliona	Baylor College of Medicine	\$4,500,000
23	RP240579	HIHRRA	2.3	Renal Clearable Nano Delivery Systems for Maximizing Anti-tumor Immunity in Breast Cancer Brain Metastasis Treatment	Zheng, Jie	The University of Texas at Dallas	\$250,000
24	RP240521	CFSA	2.3	Pediatric Cancer Data Core	Xie, Yang	The University of Texas Southwestern Medical Center	\$1,999,760
25	RP240518	CIA	2.4	Adapting radiotherapy clinical trials to treatment response and artificial intelligence innovations	Desai, Neil	The University of Texas Southwestern Medical Center	\$1,460,229
26	RP240462	HIHRRA	2.5	Development of an Endoscopic Nuclear Imaging Capsule for Radio-Guided Cancer Surgery	Zannoni, Elena Maria	The University of Texas at Austin	\$250,000
27	RP240501	HIHRRA	2.6	Delivering Immunotherapy more effectively to glioblastoma with a "magnetic switch"	Qin, Zhenpeng	The University of Texas at Dallas	\$250,000
28	RP240542	HIHRRA	2.6	Digital Twin Augmented Reality for Prostate Laparoscopic Surgery	Fei, Baowei	The University of Texas at Dallas	\$250,000

Rank	ID	RFA	Score	Application Title	PI	PI Org.	Budget
29	RP240454	HIHRRA	2.7	Reversing Tumor Immune Exclusion with Sphingosine- 1- Phosphate Depleting Therapeutics	Stone, Everett	The University of Texas at Austin	\$249,998
30	RP240498	HIHRRA	2.7	Improving the management of gastric peritoneal carcinomatosis with Photo- Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991
31	RP240493	HIHRRA	2.8	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000
32	RP240516	HIHRRA	2.9	Mapping multivalent Chromatin interactions to define the 3D genome of Clear cell renal cell carcinoma	Mani, Ram	The University of Texas Southwestern Medical Center	\$250,000
33	RP240605	HIHRRA	3.1	Stimulate Mucosal- associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484
34	RP240439	MIRA2	3.1	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000
35	RP240489	MIRA2	3.2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563
36	RP240474	MIRA2	3.6	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964

Clinical Investigator Award (CIA)  
Core Facility Support Awards (CFSA)  
High-Impact/High Risk Awards (HIHRRA)  
Multi-Investigator Research Awards (MIRA2)  
Recruitment of First-Time, Tenure Track Faculty Members (RFTTFM)

In response to an Oversight Committee member’s question about whether CPRIT limited the number of nominees an institution may submit for each cycle of the First-Time Tenure-Track award, Dr. Le Beau explained that CPRIT does not have a limit. Since CPRIT has received an increasing number of applications, she has discussed potential limits with the University Advisory Committee.

An Oversight Committee member commented that some of the same applicants receive the awards. Dr. Le Beau agreed that the largest institutions have the most robust recruitment programs and submit the most applications.

An Oversight Committee member responded that there are other areas that need to grow as well, noting that since some of the institutions have all the tools, they are at an advantage. The

member indicated that it is up to the board to address this, as there are ways to offset the balance. Dr. Le Beau explained that CPRIT shares the goal of expanding opportunities across the state of Texas. She noted that the Geographic Diversity Advisory Committee (GDAC) provided feedback on awards could make the most impact, including a recruitment award for the institutions eligible for Texas Regional Excellence in Cancer (TREC) awards.

An Oversight Committee member agreed that CPRIT should look at areas outside of the major research pipeline to support the best and move forward with the goal of curing cancer. The member recommended continuing to support the GDAC considerations to address issues like these.

An Oversight Committee member referenced two core facility projects proposed for awards and asked if CPRIT ensures rural access to the core facilities mentioned and how to bring these resources out to the rural areas. Dr. Le Beau responded that CPRIT encourages core facility applicants to include a plan for regional accessibility in their applications. She reports that an increasing number of applicants incorporate plans for providing services around the state. She noted that CPRIT can monitor this through evaluation of the annual progress reports. CPRIT may consider emphasizing the need for regional expansion in renewal applications.

An Oversight Committee member reiterated that CPRIT should ensure that oncologists and TREC institutions have access to these resources and that the goal of TREC grants is to assist institutions in becoming valuable, viable research institutions that are competitive for grant awards.

#### Approval for Academic Research Awards

Presiding Officer Dr. Cummings noted that no Oversight Committee member had reported a conflict with the 36 award recommendations presented today.

#### **MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the PIC's 36 recommendations for the following academic research grant award mechanisms:

- Clinical Investigator Awards;
- Core Facility Support Awards;
- High-Impact/High-Risk Research Awards;
- Multi-Investigator Research Awards; and
- Recruitment of First-Time, Tenure Track Faculty Members.

#### Delegation of Contract Negotiation and Execution Authority

#### **MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve delegating contract negotiation authority to the CEO and CPRIT staff and to authorize the CEO to sign the contracts on behalf of CPRIT.

### Approval for Proposed Budget Increase

Ms. Doyle presented a proposed budget increase of \$49,157 for the Texas A&M Health Science Center Research Training Award grant (RP210043). She explained that the increase allows the institution to bring the CPRIT post doc stipend on parity with the NIH stipend and noted that the Oversight Committee previously approved supplemental funds for six other Research Training Awards at the May meeting.

**MOTION:**

On a motion made by Dr. Hernandez and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve Ms. Doyle's recommendation to increase the approved budget for RP210043 by \$49,157.

### Approval for Proposed FY 2025 RFAs

**MOTION:**

On a motion made by Dr. Hernandez and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the six proposed FY2025 Cycle 2 RFAs as presented by Dr. Le Beau.

### **Chief Prevention Officer Report and Grant Recommendations – Agenda Item 9, Tab 5**

Presiding Officer Dr. Cummings recognized Chief Prevention Officer Ramona Magid to provide the Prevention program update.

There were no questions for Ms. Magid following her presentation.

### **Chief Product Development Officer Report and Grant Recommendations – Agenda Item 10, Tab 6**

Presiding Officer Dr. Cummings recognized Chief Product Development Officer Dr. Ken Smith and Senior Product Development Program Manager Dr. Abria Magee to present the product development program update.

Following Dr. Magee's presentation, an Oversight Committee member asked her whether the Texas New Technology Company award funds technologies other than artificial technology. Dr. Magee explained that the RFA seeks proposals from companies developing novel technologies including machine learning, AI, and other breakthroughs outside of traditional therapeutics or devices.

There were no other questions.

## **Scientific Research and Prevention Program Committee Appointments & FY 2025 Honoraria Policy - Agenda Item 11, Tab 7**

Presiding Officer Dr. Cummings recognized Ms. Doyle to present the CEO's peer review appointments and the proposed FY 2025 honoraria policy. Ms. Doyle introduced the 28 new members of the Scientific Research and Prevention Program Committee (also called peer reviewers) and explained the FY 2025 Honoraria Policy.

### **MOTION:**

On a motion made by Dr. Hernandez, and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the CEO's 28 appointments to the Scientific Research and Prevention Program Committees.

### **MOTION:**

On a motion made by Dr. Rosenfeld, and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the FY 2025 Honoraria Policy.

## **Advisory Committees – Item 12, Tab 9**

Presiding Officer Dr. Cummings noted that two Oversight Committee advisory committees would present their annual reports and recommendations to the board. He recognized Dr. Le Beau to introduce David Gerber, M.D., Chair of the Clinical Trials Advisory Committee.

### Clinical Trials Advisory Committee Presentation

Dr. Le Beau introduced Dr. Gerber, co-director of the Office of Education and Training for the Simmons Comprehensive Cancer Center and professor in the Department of Internal Medicine at The University of Texas Southwestern Medical Center. He presented the Clinical Trials Advisory Committee (CTAC) Annual Report.

Following Dr. Gerber's report, an Oversight Committee member asked about patient eligibility for the CPRIT Clinical Trials Participation Award and whether the funds provided to the patients are tax-exempt. Dr. Gerber explained patient eligibility requirements and responded that he would look into the tax-exempt issue.

Dr Gerber responded to a member's question about whether the CTAC had considered recommending a central IRB like the one used by Children's Oncology Group, a clinical trials group supported by the National Cancer Institute, which cuts through local IRBs and allows trials to move more quickly. He noted that there is an NCI Central IRB for the cancer centers participating in NCI trials. Although industry sponsored trials do not use a central IRB nationally, they try to create a model for sites to rely on each other's IRBs. Dr. Gerber agreed that this would significantly streamline the process of initiating clinical trials.

An Oversight Committee member asked Dr. Gerber about the number of people in CPRIT-sponsored clinical trials. Dr. Gerber explained that CPRIT-sponsored clinical trials enrolled



more than 57,000 patients in multiple types of trials, including observational trials with many patients.

On behalf of the Oversight Committee, Presiding Officer Dr. Cummings thanked Dr. Gerber for his presentation and the advisory committee's work.

He asked Dr. Magee to introduce the Product Development Advisory Committee (PDAC) presenters.

#### Product Development Advisory Committee Presentation

Dr. Magee introduced the PDAC chair and vice chair, Andrew Strong, and Dr. Michele Park, to present the PDAC report.

An Oversight Committee member asked whether previous funding is necessary for a company to receive a CPRIT award. Mr. Strong responded that an awardee must verify that the company has the required matching funds to receive CPRIT funding.

An Oversight Committee member asked whether CPRIT should prioritize funding more new companies or more follow-ups. Dr. Park answered that both are important, so more dollars invested in more companies is the preferred strategy. Mr. Strong added that it is CPRIT's strategy to balance the portfolio for successful investments.

An Oversight Committee member asked whether PDAC recommended CPRIT add more product development research program staff. Mr. Strong agreed, particularly for post award management.

An Oversight Committee member asked about distribution of product development awardees across the state, and whether companies are receiving awards in the areas of the state with TREC eligible institutions. Mr. Strong responded that the CPRIT-funded companies are mostly in Houston, Dallas, and San Antonio areas. He pointed out that there are growing inter-area connections and collaboration projects.

#### **Health & Safety Code § 102.1062 Waivers – Agenda Item 13, Tab 9**

Presiding Officer Dr. Cummings recognized Ms. Doyle to present the four FY 2025 conflict of interest waivers. Ms. Doyle presented the waivers for CPRIT Program Manager for Prevention Carlton Allen, CPRIT Contract Specialist Donald Brandy, CPRIT Program Manager for Product Development Dr. Michelle Leeuwon, and a standing waiver for Review Council Members.

#### **MOTION:**

On a motion by Dr. Rosenfeld and seconded by Dr. Hernandez, the Oversight Committee voted unanimously to approve the four proposed Health and Safety Code Section 102.1062 waivers for FY 2025.

## **Amendments to 25 T.A.C. Chapter 701 – Agenda Item 14, Tab 10**

Presiding Officer Dr. David Cummings recognized Assistant General Counsel Cameron Eckel to present the proposed final order approving a rule change to Chapter 701.

There were no questions for Ms. Eckel following her presentation.

### **MOTION:**

On a motion made by Mr. Margo, and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the final order adopting the rule change to Texas Administrative Code Chapter 701.

## **Chief Operating Officer Report – Agenda Item 15, Tab 11**

### **Contract Approvals - Agenda Item 16, Tab 12**

### **Legislative Appropriations Request for the 2026-2027 Biennium – Agenda Item 17, Tab 13**

Presiding Officer Dr. Cummings recognized Deputy Executive and Chief Operating Officer Heidi McConnell to present agenda items 15-17.

An Oversight Committee member asked if the royalty payment from Merck came from a prior product development grant and how long it has been since the initiation of that grant. Ms. McConnell responded that the Merck royalty payments are associated with the grant CPRIT made to Peloton in 2010. Merck acquired Peloton several years ago and has put Welireg on the market.

### Contract Approvals and Extensions

Ms. McConnell presented the following contracts and contract renewals for Oversight Committee approval:

- The Perryman Group for the economic Assessment of the Cost of Cancer in Texas,
- Alan Boyds Consultants for due Diligence Services,
- Weaver and Tidwell for Internal Audit Services,
- Norton Rose Fulbright and McDermott Will & Emery as outside counsel,
- Wellspring intellectual property database.

Ms. McConnell also presented her recommendation to extend the FY 2024 Business and Financial Management Solutions contract through October 15.

### **MOTION:**

On a motion by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the FY 2025 contract renewals and contract extension as laid out by Ms. McConnell with The Perryman Group, Alan Boyds Consultants, Weaver and Tidwell, Norton Rose Fulbright, McDermott Will & Emery, Wellspring, and Business and Financial Management Solutions.

## Legislative Appropriations Request for the 2026-2027 Biennium

Following the contract approvals, Ms. McConnell laid out CPRIT's proposed legislative appropriations request (LAR) for the 2026-2027 biennium for the Oversight Committee's consideration.

There were no questions for Ms. McConnell following her presentation.

### **MOTION:**

On a motion made by Mr. Margo, and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve CPRIT's Legislative Appropriations Request for the 2026 – 2027 biennium.

## **Communication Report – Agenda Item 19, Tab 15**

Presiding Officer Dr. Cummings recognized Communications Director Mark Loeffler to present his report. Mr. Loeffler updated the committee members on communications activities.

There were no questions for Mr. Loeffler following his presentation.

An Oversight Committee member thanked the communications team for the daily emails.

## **Subcommittee Business – Agenda Item 20, Tab 16**

Presiding Officer Dr. Cummings proposed that Mr. Taylor join the Prevention, Product Development, and Scientific Research Subcommittees.

### **MOTION:**

On a motion by Dr. Hernandez and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the new subcommittee appointments for Mr. Taylor.

## **Internal Audit Report – Agenda Item 18, Tab 14**

### **Compliance Investigation Pursuant to Health & Safety Code § 102.26 – Agenda Item 21 Consultation with General Counsel – Agenda Item 22**

Presiding Officer Dr. Cummings recognized Daniel Graves, representing CPRIT's internal auditor Weaver & Tidwell, to give the Internal Auditor's Report, the fiscal year 2024 Annual Internal Audit Report, and three internal audit reports. Presiding Officer Dr. Cummings noted for the board that at the conclusion of Mr. Graves report and a board vote, the Oversight Committee will move into closed session to receive the Internal Audit Follow-Up Procedures Report over Information Technology General Controls.

Mr. Graves provided the internal auditor update and presented the FY 2025 Internal Audit Plan, the FY 2024 annual internal audit report, and three internal audit reports.

There were no questions for Mr. Graves following his presentation.

**MOTION:**

On a motion by Mr. Montgomery and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the internal audit reports regarding Oversight Committee Compliance, Records Management, and Communications, the FY 2025 Internal Audit Plan, and the FY 2024 Annual Internal Audit Report.

Following the vote, Presiding Officer Dr. Cummings announced the committee would go into closed session at 11:25 a.m. pursuant to Texas Government Code § 551.076 and Texas Health & Safety Code § 102.2631 to discuss the internal audit addressing information technology general controls and to consult with CPRIT’s counsel and the Chief Compliance Officer regarding an ongoing compliance investigation. He asked Ms. Doyle, Ms. McConnell, Mr. Burgess, Mr. Nance, Ms. Eckel, Ms. Cusick, Mr. Emenike, and Mr. Graves to join the Oversight Committee in the closed session.

After the closed session discussion, the Oversight Committee reconvened in open session at 11:50 a.m.

Presiding Officer Dr. Cummings noted for the record that Ms. Cusick, Mr. Emenike, and Mr. Graves left the closed session before the board discussed the ongoing compliance investigation.

**MOTION:**

On a motion by Mr. Montgomery and seconded by Dr. Rosenfeld, the Oversight Committee voted unanimously to approve the Internal Audit Follow-Up Procedures Report over Information Technology General Controls.

**Future Meeting Dates and Agenda Items – Agenda Item 23**


Presiding Officer Dr. Cummings directed members to the FY 2025 schedule for Oversight Committee and standing subcommittee meetings behind tab 17 and reminded members that the next regular Oversight Committee meeting will take place on November 20, 2024.

**Adjournment – Agenda Item 24**

**MOTION:**

There being no further business, the Oversight Committee voted unanimously to approve Presiding Officer Dr. Cummings’s motion to adjourn, which Dr. Hernandez seconded.

Presiding Officer Dr. Cummings adjourned the meeting at 11:54 a.m.

  
\_\_\_\_\_  
Signature

11/20/2024  
Date



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

*Alleming 2  
8/21/24*

August 9, 2024

Dear Oversight Committee Members:

*Cindy Barker-Laine  
8/21/2024*

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 36 grant applications totaling \$60,577,922. I have attached the PIC's recommendations for the 36 academic research grant awards.

CPRIT Chief Scientific Officer Dr. Michelle Le Beau has prepared an overview of the recommended academic research slates to assist your evaluation of the recommended awards. We intend for the overview to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overview, all the information considered by the Scientific Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The statutory process governing the approval of these grant recommendations requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations are not final until the Oversight Committee approves the awards at the meeting on August 21, 2024. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, please keep the recommendations confidential and do not disclose information to anyone until CPRIT announces the award list publicly at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

These projects recommended for awards are a major step in our efforts to mitigate the effects of cancer in Texas. If you have any questions or would like more information on the review process or any of the proposed projects, CPRIT's staff, including myself and Dr. Le Beau, are always available. Please feel free to contact us directly should you have any questions.

Thank you for being part of this endeavor.

Sincerely,  
Kristen P. Doyle  
Chief Executive Officer

Statutory Funding Priority	CIA	CFSA	HIHRRRA	MIRA2	RFTFM
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>					
superiority by attracting from outside this state additional researchers and resources					
Expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities	✓	✓		✓	✓
Address the goals of the Texas Cancer Plan	✓	✓	✓	✓	✓

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b>							
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
1	RP240545	CFSA	Renewal of CPRIT GMP Core	Lapteva, Natalia	Baylor College of Medicine	\$2,000,000	1.0
2	RR240070	RFTFM	Expanding the Accessibility and Efficacy of CAR-T Cells Through In Vivo Engineering	Labanieh, Louai	Baylor College of Medicine	\$2,000,000	1.0
3	RR240076	RFTFM	Discovery of Molecular Glue Degraders Targeting the Undruggable Cancer Proteome	Yoon, Hojong	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
4	RR240082	RFTFM	Identification of Neural Mechanisms Contributing to Chemotherapy-Associated Cognitive Impairments	Sun, Yanjun	The University of Texas Health Science Center at Houston	\$2,000,000	1.2

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b>							
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
13	RP240557	CIA	Dietary intervention to modulate the microbiome and immune response	McQuade, Jennifer	The University of Texas M. D. Anderson Cancer Center	\$1,074,727	1.8
14	RP240430	CFSA	GCC Center for Comprehensive PK/PD & Formulation	Liang, Dong	Texas Southern University	\$2,000,000	1.9
15	RP240590	HIHRRRA	Bidentate ERK Traps: Revolutionizing Combination Cancer Therapy Strategies	Dalby, Kevin	The University of Texas at Austin	\$249,996	2.0
16	RP240539	HIHRRRA	Spectroscopy for quantitative real- time imaging of radical formation in ultra-high dose rate radiation therapy	Gustavsson, Anna- Karin	Rice University	\$250,000	2.0
17	RP240508	CFSA	The Texas Decision Science Core Facility: A CPRIT Population Science Core	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$2,995,778	2.1
18	RP240446	HIHRRRA	Regulation of Transcription Factor Function by Local Chromatin Context	Soshnev, Alexey	The University of Texas at San Antonio	\$249,561	2.1
19	RP240442	CIA	Identifying and exploiting novel metabolic vulnerabilities in the treatment of kidney cancer	Courtney, Kevin	The University of Texas Southwestern Medical Center	\$913,682	2.1
20	RP240559	CFSA	High Performance Mass Spectrometry Imaging Core Facility	Brodbelt, Jennifer	The University of Texas at Austin	\$1,998,763	2.1
21	RP240441	CIA	Precision Lung Cancer Interception by Targeting High- Risk Lung Nodules	Zhang, Jianjun	The University of Texas M. D.	\$1,098,945	2.2

<b>Academic Research Award Recommendations</b> <b>Research Cycle 24.2 and Recruitment Cycle 24.12</b>							
<i>CIA: Clinical Investigator Award</i> <i>CFSA: Core Facility Support Awards</i> <i>HIHRRRA: High-Impact/High Risk Research Awards</i> <i>MIRA2: Multi-Investigator Research Awards</i> <i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Rank	App. ID	Mech.	Application Title	PI	PI organization	Budget	Final score
			Sphingosine- 1-Phosphate Depleting Therapeutics				
30	RP240498	HIHRRRA	Improving the management of gastric peritoneal carcinomatosis with Photo- Betabody Immunotherapy	Obaid, Girgis	The University of Texas at Dallas	\$248,991	2.7
31	RP240493	HIHRRRA	Engineering in vivo chimeric antigen receptor (CAR) macrophages for diffuse midline glioma	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$250,000	2.8
32	RP240516	HIHRRRA	Mapping multivalent chromatin interactions to define the 3D genome of Clear cell renal cell carcinoma	Mani, Ram	The University of Texas Southwestern Medical Center	\$250,000	2.9
33	RP240605	HIHRRRA	Stimulate Mucosal-associated Invariant T cells to Kill Cancer Cells	Huang, Shouxiong	Texas Biomedical Research Institute	\$249,484	3.1
34	RP240439	MIRA2	Innovative cell therapy approaches for hematological and solid malignancies	Neelapu, Sattva	The University of Texas M. D. Anderson Cancer Center	\$4,500,000	3.1
35	RP240489	MIRA2	Neural Regulation of Childhood Cancers	Morrison, Sean	The University of Texas Southwestern Medical Center	\$4,362,563	3.2
36	RP240474	MIRA2	Cellular Immunotherapies for Pediatric Solid Tumors	Metelitsa, Leonid	Baylor College of Medicine	\$4,497,964	3.6